Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
Rhea-AI Summary
Neurocrine Biosciences (Nasdaq: NBIX) on March 17, 2026 promoted Andrew Ratz, Ph.D., to Chief Technical Operations Officer. Dr. Ratz will lead global technical development, manufacturing and supply chain as the company expands beyond small molecules into biologics and device-based therapies.
Dr. Ratz joined Neurocrine in January 2025 as Senior Vice President of Drug Development, Delivery and Device and brings nearly 30 years of prior executive experience at Eli Lilly. He contributed to the development and registration of more than 25 medicines and holds a B.S. in Chemistry from Indiana University and a Ph.D. in Chemistry from Harvard University.
Positive
- Appointment of Andrew Ratz as Chief Technical Operations Officer on March 17, 2026
- Role covers global technical development, manufacturing, and supply chain
- Dr. Ratz joined Neurocrine in January 2025 as SVP of Drug Development, Delivery and Device
- Nearly 30 years of prior executive experience at Eli Lilly
- Contributed to development and registration of more than 25 medicines
Negative
- No specific timelines or targets provided for the biologics and device expansion
- Announcement lacks linked financial or operational metrics tied to the new role
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows peers ELAN and RDY up modestly (around 0.49% and
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2026-03-10 | Conference appearance | Neutral | -0.3% | Announcement of presentation at Stifel 2026 Virtual CNS Forum. |
| 2026-03-06 | Media feature | Positive | +1.4% | Named a "Stock to Study" in BetterInvesting Magazine article. |
| 2026-02-24 | Investor conferences | Neutral | +0.1% | Planned management presentations at multiple March investor conferences. |
| 2026-02-11 | Earnings update | Positive | -10.4% | Reported higher 2025 net product sales and provided 2026 guidance. |
| 2026-01-26 | Clinical trial start | Positive | -1.2% | Initiation of Phase 2 trial for NBI-1065890 in tardive dyskinesia. |
Earnings with strong reported growth saw a notable negative reaction, while conferences, media mentions, and clinical initiation produced relatively modest moves, often aligned with the neutral-to-positive tone of those announcements.
Over recent months, Neurocrine reported strong financial results on Feb 11, 2026, including higher 2025 net product sales and substantial cash, yet the stock fell about 10% the next day. A Phase 2 TD study start on Jan 26, 2026 and several conference presentations in February and March led to relatively small price changes. A magazine “stock to study” mention on Mar 6, 2026 coincided with a modest gain. Today’s executive promotion fits the pattern of incremental, strategic updates rather than major binary events.
Market Pulse Summary
This announcement highlights a leadership promotion aimed at strengthening technical operations as Neurocrine expands beyond small molecules into biologics and device-based therapies. The appointee brings nearly 30 years of experience and involvement in over 25 medicines, complementing recent milestones such as earnings growth and new clinical trial starts. Investors may watch how this leadership shift supports future manufacturing scale-up and execution on the existing development pipeline.
Key Terms
biologics medical
device-based therapies medical
preclinical development medical
AI-generated analysis. Not financial advice.
Dr. Ratz – who joined Neurocrine in January 2025 as Senior Vice President of Drug Development, Delivery and Device – previously spent nearly 30 years as an executive at Eli Lilly and Company. He had broad responsibility across Lilly's drug and device development and the delivery of innovative solutions spanning preclinical development through global manufacturing. Dr. Ratz contributed to the successful development and registration of more than 25 medicines across multiple therapeutic areas and drug modalities, supporting both biologic and small molecule portfolios.
"Since joining Neurocrine, Andy has brought visionary leadership and strategic focus to our R&D organization," said Kyle W. Gano, Ph.D., Chief Executive Officer, Neurocrine Biosciences. "His skills and experience will help guide the company as we advance the next generation of treatments for patients with significant unmet needs."
"My career has been shaped by a focus on turning scientific innovation into real benefits for patients," Dr. Ratz said. "As a member of Neurocrine's leadership team, I look forward to helping build momentum around our efforts to develop therapies that can meaningfully improve patients' lives."
Dr. Ratz received a Bachelor of Science degree in Chemistry from
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with
The NEUROCRINE BIOSCIENCES logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, INGREZZA and CRENESSITY are registered trademarks of Neurocrine Biosciences, Inc.
Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the Company's ability to execute its global technical development, manufacturing and supply chain strategies; the contributions Dr. Ratz may make in his role with the Company; and the value that the Company's products and/or product candidates may provide to patients. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: challenges that the Company may encounter in implementing the leadership transition; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY; risks related to the development of our product candidates; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with government and third-party regulatory and/or policy efforts which may, among other things, impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products; risks associated with competition from other therapies or products, including potential generic entrants for our products; risks associated with our ability to manage the growth of our organization; and other risks described in our periodic reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than as required by law.
© 2026 Neurocrine Biosciences, Inc. All Rights Reserved.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-appoints-andrew-ratz-phd-as-chief-technical-operations-officer-302716364.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
Who is Andrew Ratz and what role did Neurocrine (NBIX) assign him on March 17, 2026?
What responsibilities will Andrew Ratz have as Chief Technical Operations Officer at NBIX?
When did Andrew Ratz join Neurocrine Biosciences (NBIX) and what was his prior role?
What relevant experience does Andrew Ratz bring to Neurocrine (NBIX)?
Does the NBIX announcement include timelines or targets for the biologics and device expansion?
